TY - JOUR
T1 - Monoclonal Antibodies for Atopic Dermatitis
T2 - Progress and Potential
AU - Vakharia, Paras P.
AU - Silverberg, Jonathan I
N1 - Funding Information:
Funding This publication was made possible with support from the Agency for Healthcare Research and Quality (AHRQ), Grant number K12 HS023011, and the Dermatology Foundation.
Publisher Copyright:
© 2017, Springer International Publishing AG.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Atopic dermatitis (AD) is a complex and heterogeneous inflammatory skin disorder with a profound symptom and lesional burden. Moderate-to-severe AD is particularly challenging to manage, as topical treatments are often inadequate and the systemic immunosuppressants are limited by concerns of toxicity and tolerability. Recent AD research has elucidated the mechanisms and immunologic factors involved in AD pathogenesis. These breakthroughs have led to the development of multiple therapeutic monoclonal antibodies that are directed against specific immunologic targets. This review provides an overview on the pathogenesis of AD as well as the rationale for the targets of various monoclonal antibodies. Additionally, this review explores the efficacy and safety of use for various monoclonal antibodies in the management of AD, as well as the potential role of these agents in the treatment of AD.
AB - Atopic dermatitis (AD) is a complex and heterogeneous inflammatory skin disorder with a profound symptom and lesional burden. Moderate-to-severe AD is particularly challenging to manage, as topical treatments are often inadequate and the systemic immunosuppressants are limited by concerns of toxicity and tolerability. Recent AD research has elucidated the mechanisms and immunologic factors involved in AD pathogenesis. These breakthroughs have led to the development of multiple therapeutic monoclonal antibodies that are directed against specific immunologic targets. This review provides an overview on the pathogenesis of AD as well as the rationale for the targets of various monoclonal antibodies. Additionally, this review explores the efficacy and safety of use for various monoclonal antibodies in the management of AD, as well as the potential role of these agents in the treatment of AD.
UR - http://www.scopus.com/inward/record.url?scp=85028760822&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028760822&partnerID=8YFLogxK
U2 - 10.1007/s40259-017-0241-6
DO - 10.1007/s40259-017-0241-6
M3 - Article
C2 - 28853008
AN - SCOPUS:85028760822
SN - 1173-8804
VL - 31
SP - 409
EP - 422
JO - BioDrugs
JF - BioDrugs
IS - 5
ER -